Long-term outcomes in heart transplantation using donors with a history of past and present cocaine use

Similar documents
Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients

Should Orthotopic Heart Transplantation Using Marginal Donors Be Limited to Higher Volume Centers?

Heart-lung transplantation: adult indications and outcomes

The Effect of Ventricular Assist Devices on Post-Transplant Mortality

Factors associated with 5-year survival in older heart transplant recipients

Heart/Lung Transplant. Populations Interventions Comparators Outcomes Individuals: With end-stage cardiac and pulmonary disease.

We have no disclosures

Metabolic risk factors are increasingly being recognized

Heart/Lung Transplant

Meyer, D; et al. The Future Direction of the Adult Heart Allocation System in the United States. Am J Transplant 2015; Jan 15(1):

Should Heart Transplant Recipients With Early Graft Failure Be Considered for Retransplantation?

Echocardiography analysis in renal transplant recipients

Corneal transplantation: HLA and age

Septuagenarians Bridged to Heart Transplantation With a Ventricular Assist Device Have Outcomes Similar to Younger Patients

Outcome after heart transplantation from older donor age: expanding the donor pool

Size and Gender Matching in Heart Transplantation Optimizing Donor Utilization in an Era of Changing Donor and Recipient Characteristics

Outcomes of adults with restrictive cardiomyopathy after heart transplantation

Outcomes Following Heart Transplantation In A National Cohort: An Analysis Of The Organ Procurement And Transplantation Network s Database

Journal Watch. April. REVIEW: Donor-recipient matching in heart transplantation HEART FAILURE AND TRANSPLANTATION

Influence of Pretransplant Panel-Reactive Antibody on Outcomes in 8,160 Heart Transplant Recipients in Recent Era

Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995

Heart-Lung Transplant

Medical Policy. MP Heart Transplant. BCBSA Ref. Policy: Last Review: 08/20/2018 Effective Date: 08/20/2018 Section: Surgery

Heart Transplant: State of the Art. Dr Nick Banner

POLICY GUIDELINES GENERAL CRITERIA

Kathryn L. O Keefe, 1 Ahmet Kilic, 1 Amy Pope-Harman, 2 Don Hayes, Jr., 2,3 Stephen Kirkby, 2,3 Robert S. D. Higgins, 1 Bryan A. Whitson 1.

Effect of ABO-Incompatible Listing on Infant Heart Transplant Waitlist Outcomes: Analysis of the United Network for Organ Sharing (UNOS) Database

Heart Transplant. Policy Number: Last Review: 8/2018 Origination: 8/2001 Next Review: 8/2019

Heart Transplantation is Dead

IMPORTANT REMINDER DESCRIPTION

Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017

Is lung transplantation survival better in infants? Analysis of over 80 infants

ORIGINAL ARTICLE. Received April 30, 2007; accepted June

Journal of the American College of Cardiology Vol. 60, No. 1, by the American College of Cardiology Foundation ISSN /$36.

Is a minimally invasive approach for re-operative aortic valve replacement superior to standard full resternotomy?

Gender-Based Analysis of Outcome After Heart Transplantation

H. Sonali Magdo 1 Kurt R. Schumacher 2 Sunkyung Yu 2 Robert J. Gajarski 3 Joshua M. Friedland-Little 4. Abstract 1 INTRODUCTION ORIGINAL ARTICLE

Pancreas After Islet Transplantation: A First Report of the International Pancreas Transplant Registry

Under-represented Populations Awaiting OHT. Eileen Hsich, MD Associate Medical Director for the Heart Transplant Assistant Professor of Medicine

Ontario s Referral and Listing Criteria for Adult Heart Transplantation

Donor Recipient Race Mismatch and Graft Survival After Pediatric Heart Transplantation

Association of parental pretransplant psychosocial assessment with post-transplant morbidity in pediatric heart transplant recipients*

ORIGINAL ARTICLE. Eric F. Martin, 1 Jonathan Huang, 3 Qun Xiang, 2 John P. Klein, 2 Jasmohan Bajaj, 4 and Kia Saeian 1

Transplant in Pediatric Heart Failure

Reduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival

Retransplant and Medical Therapy for Cardiac Allograft Vasculopathy: International Society for Heart and Lung Transplantation Registry Analysis

Heart/Lung Transplant. Description

PCI in Patients with Transplant Coronary Artery Disease. Michael S. Lee, MD, FACC, FSCAI Assistant Professor UCLA School of Medicine

Clinical correlates, outcomes and healthcare costs associated with early mechanical ventilation after kidney transplantation

Risk Factors for Death After Heart Transplantation: Does a Single-Center Experience Correlate With Multicenter Registries?

Is surgical Apgar score an effective assessment tool for the prediction of postoperative complications in patients undergoing oesophagectomy?

SELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%

Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?

Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?

Bilateral Versus Single Lung Transplant for Idiopathic Pulmonary Fibrosis

Exercise treadmill testing is frequently used in clinical practice to

Research Article New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

Substance Use Among Potential Kidney Transplant Candidates and its Impact on Access to Kidney Transplantation: A Canadian Cohort Study

Access and Outcomes Among Minority Transplant Patients, , with a Focus on Determinants of Kidney Graft Survival

Corporate Medical Policy

Dual-organ transplantation in older recipients: outcomes after heart kidney transplant versus isolated heart transplant in patients aged 65 years

Heart Transplantation & MCS in 2017 Advances & Challenges

Single-lung transplantation in the setting of aborted bilateral lung transplantation

Ammonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis

FEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery

Long-Term Renal Allograft Survival in the United States: A Critical Reappraisal

Debate: HLA matching matters in children

Outcome of heart transplantation after bridge-to-transplant strategy using various mechanical circulatory support devices

Heart Transplantation for Patients with a Fontan Procedure

Supplementary Appendix

Alternate Waiting List Strategies for Heart Transplantation Maximize Donor Organ Utilization

COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS

Hemodynamics during Humoral Rejection Events with Total Versus Standard Orthotopic Heart Transplantation

Regulatory Realities Redefining Benefit of Lung Transplant in the Current Era

Preoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry after Cardiac Surgery

Survival After Cardiac Transplantation in Patients With Hypertrophic Cardiomyopathy

Original Policy Date

Extracorporeal life support in preoperative and postoperative heart transplant management

Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database

The Effect of HLA Class I (A and B) and Class II (DR) Compatibility on Liver Transplantation Outcomes: An Analysis of the OPTN Database

WHY ADMINISTER CARDIOTONIC AGENTS?

Importance of the third arterial graft in multiple arterial grafting strategies

Selecting Patients for the SynCardia temporary Total Artificial Heart Help Your Patients Live Longer, Live Better

Heart Transplantation in Seniors European View

Original Article. Association of Human Leukocyte Antigen Donor Recipient Matching and Pediatric Heart Transplant Graft Survival

Overview of paediatric heart-lung transplantation: a global perspective

Hasan Fattah 3/19/2013

Maximizing Donor Lungs: Push and Mend. Amy Pope-Harman, MD. Klassen Research Day. January 22, 2015

Repeat Organ Transplantation in the United States,

Outcomes in Patients With Symptomatic Cerebrovascular Disease Undergoing Heart Transplantation

Pressure to expand the donor pool has affected all

PREDICTORS OF PROLONGED HOSPITAL STAY

Transfusion & Mortality. Philippe Van der Linden MD, PhD

Heart disease is the leading cause of death in the United

POST TRANSPLANT OUTCOMES IN PSC

Lung and Lobar Lung Transplant. Populations Interventions Comparators Outcomes Individuals: With end-stage pulmonary disease

Obesity is perhaps the most significant public health problem

Heart/Lung Transplant

Johns Hopkins Hospital Comprehensive Transplant Center Informed Consent Form for Thoracic Organ Recipient Evaluation

Transcription:

European Journal of Cardio-Thoracic Surgery 47 (2015) e146 e150 doi:10.1093/ejcts/ezu512 Advance Access publication 9 January 2015 ORIGINAL ARTICLE Cite this article as: Jayarajan S, Taghavi S, Komaroff E, Shiose A, Schwartz D, Hamad E et al. Long-term outcomes in heart transplantation using donors with a history of past and present cocaine use. Eur J Cardiothorac Surg 2015;47:e146 e50. a Long-term outcomes in heart transplantation using donors with a history of past and present cocaine use Senthil Jayarajan a, Sharven Taghavi a, Eugene Komaroff b, Akira Shiose c, Daniel Schwartz d, Eman Hamad d, Rene Alvarez d, Grayson Wheatley c, Thomas Sloane Guy c and Yoshiya Toyoda c, * Department of Surgery, Temple University School of Medicine, Philadelphia, PA, USA b Department of Public Health, Temple University, Philadelphia, PA, USA c Section of Cardiothoracic Surgery, Temple University School of Medicine, Philadelphia, PA, USA d Section of Cardiology, Temple University School of Medicine, Philadelphia, PA, USA * Corresponding author. Temple University Hospital, 3401 N Broad Street, Parkinson Pavilion Third Floor, Philadelphia, PA 19140, USA. Tel: +12-157-073601; fax: +12-157-071915; e-mail: yoshiya.toyoda@tuhs.temple.edu (Y. Toyoda). Received 25 July 2014; received in revised form 8 October 2014; accepted 23 October 2014 Abstract OBJECTIVES: Organ donors with a history of cocaine use are thought to be less favourable for orthotopic heart transplantation (OHT). This study examined long-term survival in OHT using donors with a history of cocaine use. METHODS: The United Network for Organ Sharing (UNOS) database was examined for primary, adult heart transplants from 2000 to 2010. Cox proportional hazards analysis using covariates associated with mortality was used to examine survival. RESULTS: There were 19 636 total OHTs with 2274 (11.6%) using donors with a history of dependent cocaine use (DCU). Of these, 1008 (44.3%) donors were current cocaine users. Recipients of DCU were more likely to be male (79.0 vs 75.7%, P < 0.001), more likely diabetic (16.5 vs 14.8%, P = 0.003) and were less likely to be sex mismatched (23.0 vs 28.6%, P < 0.001). DCU donors were older (32.5 vs 31.4 years, P < 0.001), more likely male (79.7 vs 69.8%, P < 0.001) and had higher ischaemic times (3.27 vs 3.20 h, P = 0.001). On multivariate analysis, DCU was not associated with mortality [hazard ratio (HR): 0.95, 95% CI: 0.87 1.03, P = 0.22]. Variables associated with mortality included recipient body mass index, sex mismatch, race mismatch, black race, ischaemic time, recipient creatinine, donor age, donor smoking history and mechanical ventilation or extracorporeal membrane oxygen as a bridge to transplantation. On subset analysis, CCU was not associated with mortality (HR: 0.97, 95% CI: 0.89 1.05, P = 0.42). On Kaplan Meier analysis, median survival was not different when comparing current (3890.0 days), past (3,889.0 days) and non-cocaine using donors (4165.0 days); P = 0.54. CONCLUSIONS: Use of carefully selected donors with a history of past and current cocaine use does not result in worse outcomes. Keywords: Heart failure Heart transplantation Congestive heart failure INTRODUCTION Cardiac transplantation remains the gold standard treatment for patients in end-stage heart failure [1, 2]. However, a shortage of donor organs has led to the use of donor hearts once thought to be unsuitable for transplantation [3 8]. Donors with a history of substance abuse are considered to be higher risk for cardiac transplantation [9], and there has been a reluctance to use donors with a history of cocaine use due to the drug s negative effects on the heart. Cocaine abuse can cause coronary vasospasm, leading to myocardial infarction. Repeated long-term use can lead to dilated cardiomyopathy [10 14]. However, because of the critical shortage of organ donors, the number of transplants using donors with Presented at the International Society of Heart and Lung Transplantation Annual Meeting in San Diego, CA, USA, 10 13 April 2014. a history of cocaine use has been on the rise. Previous studies have shown that donors with a history of cocaine use can be used with good short-term survival [15 17]. The goal of this study was to examine long-term survival and the development of acute rejection episodes in cardiac transplantation when using donors with past and present cocaine use. MATERIALS AND METHODS Patient population The Organ Procurement and Transplantation Network Standard Transplantation Analysis and Research data files were acquired and retrospectively reviewed. Inclusion criteria included all adults receiving heart transplantation between January 2000 and December The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

S. Jayarajan et al. / European Journal of Cardio-Thoracic Surgery e147 2010. Exclusion criteria from multivariate analysis included retransplantation and those with missing data. The dataset provides a field encoding for donors with any history of cocaine use. Recipients of donors with a history of cocaine use were compared with those without a history of cocaine use. In addition, the United Network for Organ Sharing (UNOS) database provides another field for donors with a history of current cocaine use (defined as use in the past 6 months prior to transplantation). Subset analysis was carried out in this group of patients that received a donor with a current history of cocaine use. Statistical analysis All continuous variables were reported as mean ± standard deviation and were analysed using t-test or ANOVA as appropriate. All categorical variables were reported as number ( percent) and were analysed using chi-square test. Univariate survival was determined using Kaplan Meier procedure and compared using log-rank test. Cox proportional hazards multivariate regression was used to determine the factors associated with mortality. The covariates were those that were found to have a of at most 0.1 on univariate Cox regression. All covariates missing greater than 15% of data in the registry were excluded from the analysis. Actuarial survival techniques were used to determine time to rejection. All analyses were completed using SAS 9.3 (Cary, NC, USA). RESULTS There were 19 636 total heart transplants performed during the study period. Of these, 2274 (11.6%) were carried out using donors with a history of cocaine use. Recipient characteristics A comparison of baseline recipient characteristics is given in Table 1. The two recipient groups were similar with respect to age, ethnicity, body mass index (BMI), cardiac output, pulmonary vascular resistance, race mismatch, total HLA mismatches, serum creatinine, and the use of mechanical ventilation, inhaled nitric oxide or extracorporeal membrane oxygenation (ECMO) as a bridge to transplantation. Recipients that received a donor with a history of cocaine use were more likely to be male (79.0 vs 75.7%, P < 0.001), had longer ischaemic time (3.27 vs 3.20 h, P = 0.001) and less likely to be sex-mismatched (23.0 vs 28.6%, P < 0.001). Donor characteristics A comparison of donor characteristics is given in Table 2. Donors with a history of cocaine use were older (32.5 vs 31.4, P < 0.001), more likely to be male (79.7 vs 69.8%, P < 0.001), had lower BMI (26.1 vs 26.5, P < 0.001), were more likely to have a history of heavy cigarette use (41.4 vs 21.8%, P < 0.001) and more likely to show clinical signs of infection (40.5 vs 37.0, P = 0.001). The two donor groups were similar with respect to history of diabetes, history of myocardial infarction, ABO compatibility and history of cancer. Postoperative outcomes A comparison of postoperative outcomes is given in Table 3. Number of acute rejection episodes on index hospitalization was less in recipients of cocaine-using donors (15.5 vs 12.8%, P = 0.004). Acute rejection episodes at 1 year, rate of retransplantation and length of stay were not significantly different. Survival As seen in Fig. 1, median survival was not significantly different on Kaplan Meier analysis (3843 vs 4165 days, P = 0.87). Cox proportional hazards analysis performed at 10 years is given in Table 4. Use of donors with a history of cocaine use was not significantly associated with mortality [hazard ratio (HR): 0.95, 95% CI: 0.87 1.03, P = 0.22]. Variables associated with mortality included increasing donor age (HR: 1.01, 95% CI: 1.01 1.02, P < 0.001), donor heavy cigarette use (HR: 0.95, 95% CI: 1.05 1.20, P = 0.001), worsening recipient creatinine (HR: 1.09, 95% CI: 1.06 1.11, P < 0.001), increasing recipient BMI (HR: 1.01, 95% CI: 1.00 1.01, P = 0.04), recipient Black race (HR: 1.35, 95% CI: 1.25 1.47, P < 0.001), sex mismatch (HR: 1.04, 95% CI: 1.02 1.16, P = 0.02), race mismatch (HR: 1.07, 95% CI: 1.01 1.14, P = 0.04) and the use of ECMO (HR: 2.21, 95% CI: 1.61 3.03, P < 0.001) or mechanical ventilation (HR: 2.05, 95% CI: 1.78 2.37, P < 0.001) as a bridge to transplantation. There were no significant interactions between donors with a history of cocaine use and donor age (P = 0.62), donor gender (P =0.57),recipient age (P = 0.73), recipient gender (P = 0.97) or ischaemic time (P =0.74). On subset analysis (Fig. 2), median survival in donors with current cocaine use (3890.0 days) was not significantly different from that of donors with past cocaine use (3889.0 days) or no history of cocaine use (4165.0 days); P = 0.54. In addition, on multivariate analysis, donors with a history of active cocaine use were not associated with mortality (HR: 0.97, 95% CI: 0.89 1.05, P = 0.42). DISCUSSION The toxic effects of cocaine on the heart are well established. In addition, cocaine can have negative effects on other organs, leading to renal and hepatic failure [12, 13, 15 17]. However, the critical shortage of organ donors [2] obligates us to examine donors that were once thought to be unacceptable for transplantation [14]. In this study, we used the UNOS database to examine the use of donors with a history of cocaine use in cardiac transplantation. Prior studies have shown that cardiac transplantation can be carried out using donors with a history of cocaine use with good short-term survival [15, 16]. Similar to the present study, Breike et al. used the UNOS database to examine heart transplant donors with a history of cocaine use. This study examined both current and past users of cocaine and found that survival was not affected by using such donors [15]. This analysis was carried out to 5 years post-transplantation, however, with median survival in heart transplant recipients currently exceeding 10 years [2, 18] and with numerous changes in immunosuppression medications; an analysis examining long-term survival is warranted. Prior research has shown that variables associated with survival at 10 years differ from those that are associated with survival in the short term [19]. TX & MCS

e148 S. Jayarajan et al. / European Journal of Cardio-Thoracic Surgery Table 1: Baseline recipient characteristics Age (years) 17 362 51.9 ± 12.3 2646 52.0 ± 12.6 0.57 Male gender 17 362 13 146 (75.7) 2646 2089 (79.0) <0.001 Recipient race 0.71 White 17 362 12 652 (72.8) 2646 1928 (72.9) Black 17 362 2865 (16.5) 2646 448 (16.9) Hispanic 17 362 1240 (7.1) 2646 192 (7.3) Asian 17 362 427 (2.5) 2646 53 (2.0) American Indian/Alaskan 17 362 58 (0.3) 2646 8 (0.3) Hawaiian/PI 17 362 48 (0.3) 2646 4 (0.2) Multiracial 17 362 82 (0.5) 2646 13 (0.5) Recipient BMI 17 346 26.6 ± 4.8 2645 26.7 ± 4.7 0.26 Recipient diabetes 15 418 2284 (14.8) 2395 396 (16.5) 0.03 Mean ischaemic time (h) 16 318 3.20 ± 1.05 2497 3.27 ± 3.23 0.001 Cardiac output (l/min) 15 513 4.3 ± 1.4 2399 4.2 ± 1.4 0.84 Mean PVR (Woods units) 13 383 2.4 ± 2.0 2069 2.3 ± 1.8 0.57 Sex mismatch 17 362 4972 (28.6) 2646 609 (23.0) <0.001 Race mismatch 17 362 7462 (43.0) 2646 1089 (41.2) 0.08 Number of HLA mismatches 14 789 4.6 ± 1.1 2266 4.6 ± 1.1 0.15 Creatinine prior to transplant (mg/dl) 17 012 1.37 ± 0.89 2599 135 ± 0.71 0.90 Mechanical ventilation prior to transplant 17 362 499 (2.9) 2646 72 (2.7) 0.66 Inhaled nitric oxide prior to transplant 17 362 48 (0.3) 2646 3 (0.1) 0.12 ECMO prior to transplant 17 362 90 (0.5) 2646 16 (0.6) 0.57 BMI: body mass index; ECMO: extracorporeal membrane oxygenation. Table 2: Donor characteristics Donor age (years) 17 362 31.4 ± 12.7 2646 32.5 ± 10.1 <0.001 Donor male 17 362 12 124 (69.8) 2646 2110 (79.7) <0.001 Donor BMI 17 362 26.5 ± 5.6 2646 26.1 ± 4.9 <0.001 Diabetic donor 17 340 420 (2.4) 2643 71 (2.7) 0.41 ABO compatible donor 17 362 2593 (14.9) 2646 400 (15.1) 0.81 Donor history of myocardial infarction 17 313 177 (1.0) 2639 29 (1.1) 0.72 Donor heavy cigarette use 17 271 3761 (21.8) 2634 1091 (41.4) <0.001 Donor history of cancer 17 362 318 (1.8) 2646 35 (1.3) 0.08 Donor history of infection 16 567 6131 (37.0) 2509 1017 (40.5) 0.001 BMI: body mass index. Table 3: Postoperative outcomes Acute rejection episode prior to discharge 10 558 1632 (15.5) 1742 223 (12.8) 0.004 Acute rejection episodes at 1 year 10 558 961 (9.1) 1742 150 (8.6) 0.95 Retransplant 17 362 221 (1.3) 2646 46 (1.7) 0.14 Length of stay (days) 17 192 20.2 ± 25.8 2622 19.9 ± 23.9 0.51 We found that even at 10 years post-transplantation, use of donors with a history of cocaine use was not independently associated with mortality. Subset analysis demonstrated that this holds true even when the donor has active cocaine use. Finally, we found no significant interaction between donors with a history of cocaine use and ischaemic time, donor age and recipient age. This

S. Jayarajan et al. / European Journal of Cardio-Thoracic Surgery e149 Figure 1: A comparison of median survival by Kaplan Meier analysis. Figure 2: A comparison of median survival by Kaplan Meier analysis using donors with current and past cocaine use. Table 4: Multiple variable model examining risk of mortality at 10 years Hazard ratio 95% Confidence interval Donor history cocaine 0.95 0.87 1.03 0.22 use Donor age (per year) 1.01 1.01 1.02 <0.001 Donor male gender 0.95 0.89 1.02 0.17 Donor diabetes 1.14 0.96 1.35 0.14 Donor heavy cigarette 1.12 1.05 1.20 0.001 use Ischaemic time 1.09 1.07 1.12 <0.001 (per hour) Recipient creatinine 1.09 1.06 1.11 <0.001 (per mg/dl) Recipient male gender 0.96 0.89 1.02 0.18 Recipient age (per year) 1.00 0.99 1.01 0.21 Recipient history of 1.06 0.97 1.15 0.25 diabetes Recipient BMI 1.01 1.00 1.01 0.04 White race Ref. Ref. Ref. Asian race 0.90 0.73 1.11 0.31 Black race 1.35 1.25 1.47 <0.001 Hispanic race 1.06 0.95 1.19 0.30 HLA mismatch >3 1.04 0.98 1.10 0.21 Sex mismatch 1.09 1.02 1.16 0.02 Race mismatch 1.07 1.01 1.14 0.04 ECMO as bridge to 2.21 1.61 3.03 <0.001 transplant Mechanical ventilator at transplant 2.05 1.78 2.37 <0.001 BMI: body mass index; ECMO: extracorporeal membrane oxygenation. suggests that donors with a history of cocaine use can be safely used even with older recipients and older donors, or when there is prolonged ischaemic time. Numerous donor and recipient variables were found to be associated with mortality including increasing donor age, donor s heavy cigarette use, worsening recipient creatinine, increasing recipient BMI, recipient Black race, sex mismatch, race mismatch and the use of ECMO or mechanical ventilation as a bridge to transplantation. These findings are consistent with previous studies [7, 8, 19 23]. While Breike et al. showed no difference in the development of coronary artery disease when using donors with a history of cocaine use [15], there are little data on the development of acute rejection episodes when using these donors. The present study found that acute rejection episodes on index hospitalization were actually lower in cohort that received donors with a history of cocaine use; however, there was no difference in the number of patients with acute rejection episodes at 1-year post-transplantation. The UNOS database does not provide information on institution surveillance protocols for rejection, nor does it provide discrete criteria for what constitutes a rejection episode or if they were biopsy confirmed. Further studies are needed to determine how donors with a history of cocaine use affect the development of acute rejection episodes in the long term. We found no difference in length of stay between the two cohorts, and this has been corroborated in prior studies [16]. Previous studies have shown no difference in intensive care length of stay [24]; however, these data are not available in the UNOS registry. Number of patients requiring eventual retransplantation was also similar when comparing the two groups. Further studies are needed to determine how using donors with a history of cocaine use may affect the incidence of graft failure leading to eventual retransplantation. This study was not without limitations, including those inherent to retrospective reviews. Not all confounding variables are available in the UNOS database, such as detailed immunosuppression data and socioeconomic status. In addition, detailed information on donor history of cocaine use is not available. Therefore, we were unable to determine how frequently donors used cocaine or the method in which it was used (inhalational, intravenous, smoked) and how this affected outcomes in the recipient. Similarly, information on the consumption of other recreational drugs or other high-risk behaviour was not available, and could not be analysed in the study. In conclusion, use of donors with a history of cocaine use does not appear to affect long-term survival in cardiac transplantation. This holds true even when using donors with active cocaine use. Number of acute rejection episodes at 1 year is also similar; however, further studies are needed to determine how this is affected long term. Donors with a history of cocaine use should be considered as potential donors for cardiac transplantation. TX & MCS

e150 S. Jayarajan et al. / European Journal of Cardio-Thoracic Surgery Conflict of interest: none declared. REFERENCES [1] Bove AA, Kashem A, Cross RC, Wald J, Furukawa S, Berman GO et al. Factors affecting survival after heart transplantation: comparison of preand post-1999 listing protocols. J Heart Lung Transplant 2006;25:42 7. [2] Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD et al. The registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report, 2013; focus theme: age. J Heart Lung Transplant 2013;32:951 64. [3] Jayarajan SN, Taghavi S, Komaroff E, Mangi AA. Impact of low donor to recipient weight ratios on cardiac transplantation. J Thorac Cardiovasc Surg 2013;146:1538 43. [4] Taghavi S, Jayarajan SN, Wilson LM, Komaroff E, Mangi AA. Cardiac transplantation with ABO-compatible donors has equivalent long-term survival. Surgery 2013;154:274 81. [5] Taghavi S, Jayarajan SN, Wilson LM, Komaroff E, Testani JM, Mangi AA. Cardiac transplantation can be safely performed using selected diabetic donors. J Thorac Cardiovasc Surg 2013;146:442 7. [6] Taghavi S, Wilson LM, Brann SH, Gaughan J, Mangi AA. Cardiac transplantation can be safely performed with low donor-to-recipient body weight ratios. J Card Fail 2012;18:688 93. [7] Weiss ES, Allen JG, Arnaoutakis GJ, George TJ, Russell SD, Shah AS et al. Creation of a quantitative recipient risk index for mortality prediction after cardiac transplantation (IMPACT). Ann Thorac Surg 2011;92:914 21; discussion 21 2. [8] Weiss ES, Allen JG, Kilic A, Russell SD, Baumgartner WA, Conte JV et al. Development of a quantitative donor risk index to predict short-term mortality in orthotopic heart transplantation. J Heart Lung Transplant 2012;31:266 73. [9] Jeevanandam V, Furukawa S, Prendergast TW, Todd BA, Eisen HJ, McClurken JB. Standard criteria for an acceptable donor heart are restricting heart transplantation. Ann Thorac Surg 1996;62:1268 75. [10] Chokshi SK, Moore R, Pandian NG, Isner JM. Reversible cardiomyopathy associated with cocaine intoxication. Ann Intern Med 1989;111:1039 40. [11] Hollander JE, Hoffman RS. Cocaine-induced myocardial infarction: an analysis and review of the literature. J Emerg Med 1992;10:169 77. [12] Isner JM, Chokshi SK. Cardiovascular complications of cocaine. Curr Probl Cardiol 1991;16:89 123. [13] Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med 2001;345:351 58. [14] Shea KJ, Sopko NA, Ludrosky K, Hoercher K, Smedira NG, Taylor DO et al. The effect of a donor s history of active substance on outcomes following orthotopic heart transplantation. Eur J Cardiothorac Surg 2007;31:452 56. [15] Brieke A, Krishnamani R, Rocha MJ, Li W, Patten RD, Konstam MA et al. Influence of donor cocaine use on outcome after cardiac transplantation: analysis of the United Network for Organ Sharing Thoracic Registry. J Heart Lung Transplant 2008;27:1350 2. [16] Freimark D, Czer LSC, Admon D, Aleksic I, Valenza M, Barath P et al. Donors with a history of cocaine use effect on survival and rejection frequency after heart-transplantation. J Heart Lung Transplant 1994;13: 1138 44. [17] Houser SL, MacGillivray T, Aretz HT. The impact of cocaine on the donor heart: a case report. J Heart Lung Transplant 2000;19:609 11. [18] Taylor DO, Stehlik J, Edwards LB, Aurora P, Christie JD, Dobbels F et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report-2009. J Heart Lung Transplant 2009;28:1007 22. [19] Kilic A, Weiss ES, George TJ, Arnaoutakis GJ, Yuh DD, Shah AS et al. What predicts long-term survival after heart transplantation? An analysis of 9400 ten-year survivors. Ann Thorac Surg 2012;93:669 704. [20] Blanche C, Kamlot A, Blanche DA, Kearney B, Magliato KE, Czer LS et al. Heart transplantation with donors fifty years of age and older. J Thorac Cardiovasc Surg 2002;123:810 5. [21] Kilic A, Weiss ES, Yuh DD, Shah AS, Conte JV. Factors associated with 5-year survival in older heart transplant recipients. J Thorac Cardiovasc Surg 2012;143:468 74. [22] Lietz K, John R, Mancini DM, Edwards NM. Outcomes in cardiac transplant recipients using allografts from older donors versus mortality on the transplant waiting list; implications for donor selection criteria. J Am Coll Cardiol 2004;43:1553 61. [23] Loebe M, Potapov EV, Hummel M, Weng Y, Bocksch W, Hetzer R. Medium-term results of heart transplantation using older donor organs. J Heart Lung Transplant 2000;19:957 63. [24] Freimark D, Aleksic I, Trento A, Takkenberg JJM, Valenza M, Admon D et al. Hearts from donors with chronic alcohol use: a possible risk factor for death after heart transplantation. J Heart Lung Transplant 1996;15: 150 59.